Mumbai-based drugmaker Glenmark Pharmaceuticals has launched the first fixed dose combination (FDC) of teneligliptin and pioglitazone, two diabetes management drugs, for adults with uncontrolled Type 2 diabetes. Branded as Zita Plus Pio, the combination therapy was approved by the Drug Controller General of India on Monday and is the only available DPP4 and glitazone combination drug in India.